摘要
目的探讨FOLFOX4方案治疗晚期肝癌的临床疗效及毒副反应。方法 17例晚期肝癌患者接受FOLFOX4方案(L-OHP 85mg/m2静脉滴注d1;CF 200 mg/m2静脉滴注d1,2;5-Fu 400 mg/m2静脉滴注d1,2;5-Fu 600 mg/m2持续静脉滴注d1,2;每3周重复)全身化疗,每例至少化疗2周期后评价疗效及毒副反应。结果全组17例患者均可评价疗效,无CR病例,PR 1例,SD 12例,PD 4例,总有效率5.9%,临床受益率76.5%,主要毒副反应为胃肠道及末梢神经毒性,无严重的并发症发生。结论 FOLFOX4方案治疗中晚期肝癌临床疗效可评价,安全性高,毒副反应轻,患者可耐受。
Objective To observe the clinical effect and toxicities of FOLFOX4 regimen in the treatment of patients with advanced hepatocellular cancer. Methods Seventeen patients with advanced hepatocellular cancer were treated with FOLFOX4 regimen ： L-OHP 85 mg/m2, ivgtt,d1 ;CF 200 mg/m2 ,ivgtt,d1,2 ;5-Fu 400 mg/m2 ,ivgtt,d1.2 ;and 5-Fu 600 mg/m2 ,CIA,d1.2. Three weeks were one cycle,and the effect and toxicities were evaluated after 2 cycles of chemotherapy. Results Among the 17 cases, no case was in CR, 1 case was in PR, 12 cases were in SD,4 cases were in PD. The total response rate was 5.9%. The clinical benefit rate was 76.5%. The major toxicities were gastrointestinal reaction and peripheral nerve toxicity. Conclusion FOLFOX4 regimen is a feasible systemic chemotherapy regimen for patients with advanced hepatocellular cancer, and it is effect and safe.
出处
《肿瘤基础与临床》
2011年第6期495-496,共2页
journal of basic and clinical oncology
关键词
肝癌
化疗
FOLFOX4方案
hepatocellular cancer
chemotherapy
FOLFOX4 regimen
